Autolus Therapeutics Closes $100M ADS Offering

Ticker: AUTL · Form: 8-K · Filed: 2024-03-14T00:00:00.000Z

Sentiment: bullish

Topics: financing, public-offering, cell-therapy

Related Tickers: AUTL

TL;DR

Autolus Therapeutics just raised $100M from an ADS offering to fund their cell therapy pipeline.

AI Summary

On March 14, 2024, Autolus Therapeutics plc announced the closing of its previously announced underwritten public offering of American Depositary Shares (ADSs), raising gross proceeds of approximately $100 million before deducting underwriting discounts and commissions and other offering expenses. The offering involved 10,000,000 ADSs at a public offering price of $10.00 per ADS.

Why It Matters

This capital raise provides Autolus Therapeutics with significant funding to advance its pipeline of cell therapies, potentially accelerating their development and market entry.

Risk Assessment

Risk Level: medium — While the capital raise is positive, the success of Autolus Therapeutics is still dependent on the clinical and regulatory success of its novel cell therapies.

Key Numbers

Key Players & Entities

FAQ

What was the total amount of gross proceeds raised by Autolus Therapeutics in this offering?

Autolus Therapeutics raised approximately $100 million in gross proceeds before deducting underwriting discounts and commissions and other offering expenses.

How many American Depositary Shares (ADSs) were offered?

The offering involved 10,000,000 ADSs.

What was the public offering price per ADS?

The public offering price per ADS was $10.00.

When did Autolus Therapeutics announce the closing of this offering?

The closing of the offering was announced on March 14, 2024.

What is the primary use of the funds raised from this offering?

The funds raised are intended to advance Autolus Therapeutics' pipeline of cell therapies.

From the Filing

0001730463-24-000021.txt : 20240314 0001730463-24-000021.hdr.sgml : 20240314 20240314123235 ACCESSION NUMBER: 0001730463-24-000021 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 53 CONFORMED PERIOD OF REPORT: 20240314 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240314 DATE AS OF CHANGE: 20240314 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Autolus Therapeutics plc CENTRAL INDEX KEY: 0001730463 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38547 FILM NUMBER: 24748731 BUSINESS ADDRESS: STREET 1: THE MEDIAWORKS STREET 2: 191 WOOD LANE CITY: LONDON STATE: X0 ZIP: W12 7FP BUSINESS PHONE: 44 20 3829 6230 MAIL ADDRESS: STREET 1: THE MEDIAWORKS STREET 2: 191 WOOD LANE CITY: LONDON STATE: X0 ZIP: W12 7FP FORMER COMPANY: FORMER CONFORMED NAME: Autolus Therapeutics Ltd DATE OF NAME CHANGE: 20180205 8-K 1 autl-20240314.htm 8-K autl-20240314 0001730463 FALSE 0001730463 2024-03-14 2024-03-14 0001730463 sic:Z8880 2024-03-14 2024-03-14 0001730463 us-gaap:CommonClassAMember 2024-03-14 2024-03-14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2024 Autolus Therapeutics plc (Exact name of registrant as specified in its Charter) England and Wales 001-38547 Not applicable (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) The Mediaworks 191 Wood Lane London W12 7FP United Kingdom (Address of principal executive offices)(Zip Code) (44) 20 3829 6230 (Registrant's telephone number, including area code) Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered American Depositary Shares, each representing one ordinary share, nominal value $0.000042 per share AUTL The Nasdaq Global Select Market Ordinary shares, nominal value $0.000042 per share* * The Nasdaq Stock Market LLC * * Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC. Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 2.02 Results of Operations and Financial Conditions. On March 14, 2024, Autolus Therapeutics plc (the “ Company ”) issued a press release announcing its recent business highlights and financial results for year e

View on Read The Filing